{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:51:03Z","timestamp":1793947863773,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identifying and treating individuals with high risk of progression from latent tuberculosis infection to active tuberculosis (TB) disease is critical for eliminating the disease. We aimed to conduct a systematic review and meta-regression analysis to quantify the dose-response relationship between interferon-gamma release assay (IGRA) levels and the risk of progression to active TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed and Embase from 1 January 2001 to 10 May 2020 for longitudinal studies that reported the risk of progression from latent to active TB as a function of baseline IGRA values. We used a novel Bayesian meta-regression method to pool effect sizes from included studies and generate a continuous dose-response risk curve. Our modeling framework enabled us to incorporate random effects across studies, and include data with different IGRA ranges across studies. The quality of included studies were assessed using the Newcastle-Ottawa scale (NOS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 34 studies representing 581,956 person-years of follow-up with a total of 788 incident cases of TB in the meta-regression analysis. Higher levels of interferon-gamma were associated with increased risk of progression to active tuberculosis. In the dose-response curve, the risk increased sharply between interferon-gamma levels 0 and 5\u2009IU\/ml, after which the risk continued to increase moderately but at a slower pace until reaching about 15\u2009IU\/ml where the risk levels off. Compared to 0\u2009IU\/ml, the relative risk of progression to active TB among those with interferon-gamma levels of 0.35, 1, 5, 10, 15, and 20\u2009IU\/ml were: 1.64 (1.28\u20132.08), 2.90 (2.02\u20133.88), 11.38 (6.64\u201316.38), 19.00 (13.08\u201326.90), 21.82 (14.65\u201332.57), and 22.31 (15.43\u201333.00), respectively. The dose-response relationship remains consistent when limiting the analysis to studies that scored highest in the NOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The current practice of dichotomizing IGRA test results simplifies the TB infection disease continuum. Evaluating IGRA test results over a continuous scale could enable the identification of individuals at greatest risk of progression to active TB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06141-4","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T08:02:57Z","timestamp":1621670577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Jorge R.","family":"Ledesma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-5691","authenticated-orcid":false,"given":"Hmwe H.","family":"Kyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"issue":"10258","key":"6141_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204\u201322 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673620309259.","journal-title":"Lancet"},{"issue":"10159","key":"6141_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789\u2013858 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673618323353.","journal-title":"Lancet"},{"issue":"10","key":"6141_CR3","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RMGJ Houben","year":"2016","unstructured":"Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical Modelling. PLoS Med. 2016;13(10):e1002152 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27780211.","journal-title":"PLoS Med"},{"issue":"3\u20134","key":"6141_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","volume":"43","author":"S Kiazyk","year":"2017","unstructured":"Kiazyk S, Ball TB. Latent tuberculosis infection: an overview. Can Commun Dis Rep. 2017;43(3\u20134):62\u20136 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29770066.","journal-title":"Can Commun Dis Rep"},{"issue":"10010","key":"6141_CR5","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(15)00323-2","volume":"386","author":"MX Rangaka","year":"2015","unstructured":"Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet. 2015;386(10010):2344\u201353 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673615003232.","journal-title":"Lancet."},{"key":"6141_CR6","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijid.2019.01.048","volume":"80","author":"G Gualano","year":"2019","unstructured":"Gualano G, Mencarini P, Lauria FN, Palmieri F, Mfinanga S, Mwaba P, et al. Tuberculin skin test \u2013 outdated or still useful for latent TB infection screening? Int J Infect Dis. 2019;80:S20\u20132 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197121930061X.","journal-title":"Int J Infect Dis"},{"key":"6141_CR7","first-page":"1","volume":"2013","author":"A Trajman","year":"2013","unstructured":"Trajman A, Steffen RE, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med. 2013;2013:1\u201311 Available from: http:\/\/www.hindawi.com\/journals\/pm\/2013\/601737\/.","journal-title":"Pulm Med"},{"key":"6141_CR8","unstructured":"World Health Organization (WHO). Global tuberculosis report 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329368\/9789241565714-eng.pdf?ua=1. Accessed 23 June 2020."},{"key":"6141_CR9","doi-asserted-by":"crossref","unstructured":"Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;m549 Available from: http:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.m549.","DOI":"10.1136\/bmj.m549"},{"issue":"7","key":"6141_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/thoraxjnl-2017-211147","volume":"73","author":"BA Winje","year":"2018","unstructured":"Winje BA, White R, Syre H, Skutlaberg DH, Oftung F, Mengshoel AT, et al. Stratification by interferon-\u03b3 release assay level predicts risk of incident TB. Thorax. 2018;73(7):652\u201361 Available from: http:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2017-211147.","journal-title":"Thorax"},{"issue":"10","key":"6141_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1164\/rccm.201502-0232OC","volume":"191","author":"J-P Zellweger","year":"2015","unstructured":"Zellweger J-P, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, et al. Risk assessment of tuberculosis in contacts by IFN-\u03b3 release assays. A tuberculosis network European trials group study. Am J Respir Crit Care Med. 2015;191(10):1176\u201384. https:\/\/doi.org\/10.1164\/rccm.201502-0232OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"6141_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","volume":"5","author":"JR Andrews","year":"2017","unstructured":"Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med. 2017;5(4):282\u201390 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213260017300607.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"6141_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/thoraxjnl-2015-208228","volume":"71","author":"TS Hermansen","year":"2016","unstructured":"Hermansen TS, Lillebaek T, Langholz Kristensen K, Andersen PH, Ravn P. Prognostic value of interferon-\u03b3 release assays, a population-based study from a TB low-incidence country. Thorax. 2016;71(7):652\u20138 Available from: http:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2015-208228.","journal-title":"Thorax"},{"issue":"11","key":"6141_CR14","doi-asserted-by":"publisher","first-page":"e0187313","DOI":"10.1371\/journal.pone.0187313","volume":"12","author":"J Jonsson","year":"2017","unstructured":"Jonsson J, Westman A, Bruchfeld J, Stureg\u00e5rd E, Gaines H, Sch\u00f6n T. A borderline range for Quantiferon gold in-tube results. Shams (Amir) Homayoun, editor. PLoS One. 2017;12(11):e0187313. https:\/\/doi.org\/10.1371\/journal.pone.0187313.","journal-title":"PLoS One"},{"issue":"1","key":"6141_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6673-8-1","volume":"8","author":"A Nienhaus","year":"2013","unstructured":"Nienhaus A, Costa JT. Screening for tuberculosis and the use of a borderline zone for the interpretation of the interferon-\u03b3 release assay (IGRA) in Portuguese healthcare workers. J Occup Med Toxicol. 2013;8(1):1 Available from: http:\/\/occup-med.biomedcentral.com\/articles\/10.1186\/1745-6673-8-1.","journal-title":"J Occup Med Toxicol"},{"key":"6141_CR16","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"G Wells","year":"2011","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: Department of Epidemiology and Community Medicine, University of Ottawa, Canada; 2011. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"6141_CR17","volume-title":"Trimmed constrained mixed effects models: formulations and algorithms","author":"P Zheng","year":"2019","unstructured":"Zheng P, Aravkin AY, Barber R, Sorensen RJD, Murray CJL. Trimmed constrained mixed effects models: formulations and algorithms; 2019. Available from: http:\/\/arxiv.org\/abs\/1909.10700"},{"key":"6141_CR18","doi-asserted-by":"crossref","unstructured":"Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018;31(4) Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30021818.","DOI":"10.1128\/CMR.00021-18"},{"issue":"4","key":"6141_CR19","doi-asserted-by":"publisher","first-page":"e1002787","DOI":"10.1371\/journal.pmed.1002787","volume":"16","author":"GJ Churchyard","year":"2019","unstructured":"Churchyard GJ, Swindells S. Controlling latent TB tuberculosis infection in high-burden countries: a neglected strategy to end TB. PLoS Med. 2019;16(4):e1002787 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31013273.","journal-title":"PLoS Med"},{"issue":"3","key":"6141_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1378\/chest.12-0142","volume":"142","author":"SK Sharma","year":"2012","unstructured":"Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest. 2012;142(3):761\u201373 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369212605224.","journal-title":"Chest"},{"issue":"3","key":"6141_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/QAI.0b013e31820b07ab","volume":"56","author":"A Cattamanchi","year":"2011","unstructured":"Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. JAIDS J Acquir Immune Defic Syndr. 2011;56(3):230\u20138 Available from: http:\/\/content.wkhealth.com\/linkback\/openurl?sid=WKPTLP:landingpage&an=00126334-201103010-00006.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"10","key":"6141_CR22","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","volume":"190","author":"M Sester","year":"2014","unstructured":"Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in Immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190(10):1168\u201376. https:\/\/doi.org\/10.1164\/rccm.201405-0967OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"6141_CR23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1086\/597351","volume":"48","author":"MC Aichelburg","year":"2009","unstructured":"Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-\u03b3 release assay in HIV-1\u2013infected individuals. Clin Infect Dis. 2009;48(7):954\u201362 Available from: https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1086\/597351.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6141_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/QAI.0000000000000109","volume":"66","author":"JS Doyle","year":"2014","unstructured":"Doyle JS, Bissessor M, Denholm JT, Ryan N, Fairley CK, Leslie DE. Latent tuberculosis screening using interferon-gamma release assays in an Australian HIV-infected cohort. JAIDS J Acquir Immune Defic Syndr. 2014;66(1):48\u201354 Available from: http:\/\/content.wkhealth.com\/linkback\/openurl?sid=WKPTLP:landingpage&an=00126334-201405010-00007.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"4","key":"6141_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5588\/ijtld.18.0198","volume":"23","author":"S Lee","year":"2019","unstructured":"Lee S, Lee JE, Kang JS, Lee SO, Lee SH. Long-term performance of the IGRA to predict and prevent active tuberculosis development in HIV-infected patients. Int J Tuberc Lung Dis. 2019;23(4):422\u20137 Available from: https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.18.0198.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"6141_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/MOP.0b013e3283350301","volume":"22","author":"DA Lewinsohn","year":"2010","unstructured":"Lewinsohn DA, Lobato MN, Jereb JA. Interferon-\u03b3 release assays: new diagnostic tests for mycobacterium tuberculosis infection, and their use in children. Curr Opin Pediatr. 2010;22(1):71\u20136 Available from: http:\/\/journals.lww.com\/00008480-201002000-00013.","journal-title":"Curr Opin Pediatr"},{"issue":"8","key":"6141_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/INF.0b013e3181a16394","volume":"28","author":"T Haustein","year":"2009","unstructured":"Haustein T, Ridout DA, Hartley JC, Thaker U, Shingadia D, Klein NJ, et al. The likelihood of an indeterminate test result from a whole-blood interferon-\u03b3 release assay for the diagnosis of mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J. 2009;28(8):669\u201373 Available from: http:\/\/journals.lww.com\/00006454-200908000-00001.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"6141_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1542\/peds.2007-3618","volume":"123","author":"J Lighter","year":"2009","unstructured":"Lighter J, Rigaud M, Eduardo R, Peng C-H, Pollack H. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB gold in-tube test. Pediatrics. 2009;123(1):30\u20137. https:\/\/doi.org\/10.1542\/peds.2007-3618.","journal-title":"Pediatrics"},{"issue":"1","key":"6141_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-\u03b3 release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45\u201355 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309911702109.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"6141_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1513\/AnnalsATS.201408-394OC","volume":"12","author":"N Altet","year":"2015","unstructured":"Altet N, Dominguez J, de Souza-Galv\u00e3o M-L, Jim\u00e9nez-Fuentes M\u00c1, Mil\u00e0 C, Solsona J, et al. Predicting the development of tuberculosis with the tuberculin skin test and QuantiFERON testing. Ann Am Thorac Soc. 2015;12(5):680\u20138. https:\/\/doi.org\/10.1513\/AnnalsATS.201408-394OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"6141_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1164\/rccm.201905-0969OC","volume":"201","author":"RK Gupta","year":"2020","unstructured":"Gupta RK, Lipman M, Jackson C, Sitch AJ, Southern J, Drobniewski F, et al. Quantitative IFN-\u03b3 release assay and tuberculin skin test results to predict incident tuberculosis. A prospective cohort study. Am J Respir Crit Care Med. 2020;201(8):984\u201391. https:\/\/doi.org\/10.1164\/rccm.201905-0969OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"6141_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-016-0215-7","volume":"5","author":"WM Bramer","year":"2016","unstructured":"Bramer WM, Giustini D, Kramer BMR. Comparing the coverage, recall, and precision of searches for 120 systematic reviews in Embase, MEDLINE, and Google scholar: a prospective study. Syst Rev. 2016;5(1):39 Available from: http:\/\/www.systematicreviewsjournal.com\/content\/5\/1\/39.","journal-title":"Syst Rev"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06141-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06141-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06141-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T08:04:00Z","timestamp":1621670640000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06141-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06141-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"467"}}